P53 ABNORMALITIES IN HUMAN PARATHYROID CARCINOMA

被引:25
作者
CRYNS, VL
RUBIO, MP
THOR, AD
LOUIS, DN
ARNOLD, A
机构
[1] MASSACHUSETTS GEN HOSP, ENDOCRINE ONCOL LAB, BOSTON, MA 02114 USA
[2] MASSACHUSETTS GEN HOSP, MOLEC NEUROONCOL LAB, BOSTON, MA 02114 USA
[3] MASSACHUSETTS GEN HOSP, NEUROSURG SERV, BOSTON, MA 02114 USA
[4] MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA
[5] HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA
关键词
D O I
10.1210/jcem.78.6.8200932
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Two cell cycle regulators have been implicated in the pathogenesis of parathyroid neoplasms: rearrangement/overexpression of the PRAD1/cyclin D1 gene in parathyroid adenomas and inactivation of the retinoblastoma tumor suppressor gene in parathyroid carcinomas. We examined parathyroid tumors for evidence of molecular genetic abnormalities in another cell cycle regulator, the p53 tumor suppressor gene. Allelic loss of the p53 gene was observed in parathyroid carcinomas from 2 of 6 genetically informative patients. Moreover, 2 of 9 patients' parathyroid carcinomas had nuclear p53 protein detectable by immunohistochemical analysis, a finding that often reflects mutational stabilization of the p53 protein. Of these two p53-immunopositive carcinomas, 1 had p53 allelic loss and 1 was genetically uninformative. In contrast, none of 20 informative parathyroid adenomas exhibited p53 allelic loss; 1 of 19 adenomas had a focal region of nuclear p53 protein staining. Single strand conformation polymorphism analysis of exons 5-9 of the p53 gene did not reveal mutations in any parathyroid neoplasm, suggesting that such mutations in parathyroid tumors may lie outside of these conserved regions. The finding of both p53 allelic loss and abnormal p53 protein expression in parathyroid carcinomas implicates p53 in the pathogenesis of a subset of these tumors.
引用
收藏
页码:1320 / 1324
页数:5
相关论文
共 57 条
[21]  
Hayashi K, 1991, PCR Methods Appl, V1, P34
[22]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[23]   INCREASED EXPRESSION OF MUTANT FORMS OF P53 ONCOGENE IN PRIMARY LUNG-CANCER [J].
IGGO, R ;
GATTER, K ;
BARTEK, J ;
LANE, D ;
HARRIS, AL .
LANCET, 1990, 335 (8691) :675-679
[24]  
ITO T, 1992, CANCER RES, V52, P1369
[25]  
KAY S, 1973, ARCH PATHOL, V96, P316
[26]   A HYPERVARIABLE RFLP ON CHROMOSOME 17P13 IS DEFINED BY AN ARBITRARY SINGLE COPY PROBE P144-D6 [HGM9 NO-D17S34] [J].
KONDOLEON, S ;
VISSING, H ;
LUO, XY ;
MAGENIS, RE ;
KELLOGG, J ;
LITT, M .
NUCLEIC ACIDS RESEARCH, 1987, 15 (24) :10605-10605
[27]   P53 GENE-MUTATIONS AND PROTEIN ACCUMULATION IN HUMAN OVARIAN-CANCER [J].
KUPRYJANCZYK, J ;
THOR, AD ;
BEAUCHAMP, R ;
MERRITT, V ;
EDGERTON, SM ;
BELL, DA ;
YANDELL, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) :4961-4965
[28]  
LEVIN KE, 1987, SURGERY, V101, P649
[29]   THE P53 TUMOR SUPPRESSOR GENE [J].
LEVINE, AJ ;
MOMAND, J ;
FINLAY, CA .
NATURE, 1991, 351 (6326) :453-456
[30]   COMPARATIVE-STUDY OF P53 GENE AND PROTEIN ALTERATIONS IN HUMAN ASTROCYTIC TUMORS [J].
LOUIS, DN ;
VONDEIMLING, A ;
CHUNG, RY ;
RUBIO, MP ;
WHALEY, JM ;
EIBL, RH ;
OHGAKI, H ;
WIESTLER, OD ;
THOR, AD ;
SEIZINGER, BR .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1993, 52 (01) :31-38